InvestorsObserver
×
News Home

Has Ultragenyx Pharmaceutical Inc (RARE) Stock's Recent Performance Changed Wall Street's Expectations?

Wednesday, April 08, 2020 11:01 AM | InvestorsObserver Analysts

Mentioned in this article

Has Ultragenyx Pharmaceutical Inc (RARE) Stock's Recent Performance Changed Wall Street's Expectations?

InvestorsObserver is giving Ultragenyx Pharmaceutical Inc (RARE) an Analyst Rating Rank of 76, meaning RARE is ranked higher by analysts than 76% of stocks. The average projection by analysts for RARE is $74.153 over the next 12 months and analyst’s classify the stock as a Strong Buy

Overall Score - 4.8
Wall Street analysts are rating RARE a Strong Buy today. Find out what this means to you and get the rest of the rankings on RARE!

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.

Investors Observer takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With Ultragenyx Pharmaceutical Inc Stock Today?

Ultragenyx Pharmaceutical Inc (RARE) stock has risen 1.85% while the S&P 500 is flat 0% as of 10:58 AM on Wednesday, Apr 8. RARE is up $0.94 from the previous closing price of $50.71 on volume of 22,263 shares. Over the past year the S&P 500 has fallen -7.60% while RARE is down -28.27%. RARE lost -$7.12 per share the over the last 12 months.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App